| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0165-5728(99)00029-6 |
| P698 | PubMed publication ID | 10496186 |
| P2093 | author name string | J Biollaz | |
| T Buclin | |||
| A Ythier | |||
| F Spertini | |||
| A Munafo | |||
| P A Buchwalder | |||
| L E Rothuizen | |||
| I Trinchard | |||
| P2860 | cites work | Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-alpha-stimulated transcription factor ISGF3 | Q28245207 |
| Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) | Q34375520 | ||
| Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions | Q35819856 | ||
| Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. | Q36896777 | ||
| Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy | Q37368148 | ||
| Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b | Q39788229 | ||
| Clinical toxicity of the interferons. | Q40390091 | ||
| Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis | Q40401700 | ||
| Circulating adhesion molecules and inflammatory mediators in demyelination: a review | Q40546566 | ||
| The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis | Q40546571 | ||
| Prescribing recommendations for interferon-Beta in multiple sclerosis | Q40884039 | ||
| Management of multiple sclerosis | Q41644495 | ||
| Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis | Q43516653 | ||
| Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B. | Q43755703 | ||
| Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin | Q45192678 | ||
| Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse | Q47964620 | ||
| In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis | Q48485957 | ||
| Pretreatment of astrocytes with interferon-alpha/beta prevents neuronal mitochondrial respiratory chain damage. | Q48568579 | ||
| Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. | Q53349653 | ||
| Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers. | Q54398599 | ||
| Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. | Q54561040 | ||
| Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis | Q57912405 | ||
| Recombinant Interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells | Q61863563 | ||
| The Effects of Various Cytokines on Interleukin-6 and Interferon-α Synthesis in Human Peripheral Blood Mononuclear Cells | Q67687156 | ||
| Highly sensitive enzyme immunoassay of human interferon-beta 1 | Q69500129 | ||
| Interferon beta in multiple sclerosis | Q70650970 | ||
| Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group | Q70650973 | ||
| Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration | Q71123729 | ||
| Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients | Q71744345 | ||
| Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers | Q71763735 | ||
| Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma | Q71763737 | ||
| Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously | Q72167063 | ||
| Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins | Q72194401 | ||
| Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up | Q72756567 | ||
| Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers | Q73326511 | ||
| Correlation between interferon production and clinical disease activity in patients with multiple sclerosis | Q73590792 | ||
| Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) | Q73624496 | ||
| IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months | Q73669697 | ||
| Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration | Q77348361 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 131-141 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Journal of Neuroimmunology | Q15716691 |
| P1476 | title | Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers | |
| P478 | volume | 99 |
| Q53151534 | A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. |
| Q37596887 | A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects |
| Q34812643 | Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers |
| Q33209050 | Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? |
| Q40402453 | Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. |
| Q35772872 | Autoimmunity through cytokine-induced dendritic cell activation |
| Q35483221 | Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. |
| Q81282674 | Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study |
| Q24556513 | Cross-regulation of TNF and IFN-alpha in autoimmune diseases |
| Q34582889 | Dendritic cell subsets in health and disease. |
| Q34508451 | Disease modifying agents for multiple sclerosis |
| Q36834293 | Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis |
| Q36260729 | Early treatment and dose optimisation BENEFIT and BEYOND. |
| Q89498899 | Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report |
| Q53871933 | IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. |
| Q74022709 | Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis |
| Q74012645 | Interferon beta1a treatment modulates TH1 expression in gammadelta + T cells from relapsing-remitting multiple sclerosis patients |
| Q34427729 | Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response |
| Q36106748 | Interferon-beta1a treatment for multiple sclerosis |
| Q35556109 | Interferon-β in the treatment of relapsing–remitting multiple sclerosis |
| Q35892268 | Is multiple sclerosis a disease that requires frequent beta interferon dosing? |
| Q44678751 | Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis? |
| Q34750099 | Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis |
| Q51648083 | Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta. |
| Q33243924 | Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis |
| Q73153718 | Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis |
| Q36385464 | Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation |
| Q77128128 | Multiple sclerosis: deficient in vitro responses of blood mononuclear cells to IFN-beta |
| Q33829033 | PEGylated interferon-beta modulates the acute inflammatory response and recovery when combined with forced exercise following cervical spinal contusion injury |
| Q37356528 | Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach |
| Q35135977 | Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study |
| Q35164752 | Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis |
| Q40201787 | Phosphoinositide 3-kinase regulates a subset of interferon-alpha-stimulated genes |
| Q44211849 | Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans |
| Q34022587 | Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials |
| Q73276254 | Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS |
| Q36842201 | Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis |
| Q37735773 | Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS. |
| Q31149165 | Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis |
| Q36139277 | Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis |
| Q57085810 | The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders |
| Q36260724 | The importance of maintaining effective therapy in multiple sclerosis |
| Q37207014 | Transcription profiling of rheumatic diseases |
| Q28509359 | Twist mediates suppression of inflammation by type I IFNs and Axl |
| Q73035377 | Type 1 IFNs in human versus mouse |
| Q37808291 | Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. |
| Q34590280 | Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response |
| Q30755026 | [Interferons and neurologic diseases]. |
Search more.